Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Revenue increased 11.4 per cent to Rs. 8,545 crore
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Stable profits, low leverage to keep credit profiles comfortable
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Lupin is the 6th largest company in the Indian Pharmaceutical Market
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Subscribe To Our Newsletter & Stay Updated
